Recordati : Performance opérationnelle au rendez-vous malgré une topline en-deçà des attentes
>Les maladies rares en locomotive de la croissance - Recordati a publié vendredi en séance ses chiffres au titre du T3 2024. Les ventes sur la période ressortent 2.8% inférieures aux attentes à 557.4 M€ (+9% yoy). Nous soulignons i/ une dynamique de croissance toujours tirée par le segment des maladies rares (+14,5% tcc) sur les 9 premiers mois, l'activité continue de bénéficier de l'endocrinologie (+36%) et de l'oncologie (+17%), ii/ la croissance de la franchise SPC...Recordati-Industria Chimica e Farmaceutica is a pharmaceutical group based in Italy. Co.'s operations are divided into two operating segments: pharmaceuticals (and pharmaceutical chemicals) and orphan drugs. Co.'s products include ZANIPRESS®/ZANEXTRA®/LERCAPREL®/LERCARIL®, an antihypertensive drug; ZANIDIP®/CORIFEO®/LERCADIP® (lercanidipine), an antihypertensive drug discovered and developed in Co.'s research laboratories; UROREC® (silodosin), a new drug indicated for the treatment of benign prostatic hyperplasia; and LIVAZO®/ALIPZA® (pitavastatin), a statin for the treatment of dyslipidemia, among others.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.